Aldeyra Therapeutics Inc. (ALDX)

7.95
NASDAQ : Health Technology
Prev Close 7.95
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.90 / 11.90
Avg Volume 113.00K
Exchange NASDAQ
Shares Outstanding 20.11M
Market Cap 171.93M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aldeyra Therapeutics Joins The Russell 3000® And 2000® Indexes

Aldeyra Therapeutics Joins The Russell 3000® And 2000® Indexes

LEXINGTON, Mass., June 25, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Announces 2018 Research Day

Aldeyra Therapeutics Announces 2018 Research Day

LEXINGTON, Mass., June 20, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Presents Dry Eye Disease Phase 2a Clinical Trial Results At The Association For Research In Vision And Ophthalmology 2018 Annual Meeting

Data Demonstrate Statistically and Clinically Significant Activity of Topical Ocular 0.1% Reproxalap Across a Broad Array of Signs and Symptoms

2 Small Biopharmas With Case of 'Hiccups'

2 Small Biopharmas With Case of 'Hiccups'

Insiders are taking advantage of opportunities in Intra-Cellular Therapies and Aldeyra.

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

Aldeyra Leaps on Data for Dry Eye Disease Treatment - Biotech Movers

The Lexington, Mass.-based company unveiled results from its Phase 2a study of ADX-102 in dry eye disease. Other biotech movers in premarket trading on Sept. 12 include Sage Therapeutics and Intercept Pharmaceuticals.

Aldeyra Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference

Aldeyra Therapeutics To Present At The Cowen And Company 36th Annual Health Care Conference

Presentation to Include Additional Data From Aldeyra's Recently Completed Phase IIa Clinical Trial of NS2 in Allergic Conjunctivitis